QuassinCAS# 76-78-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 76-78-8 | SDF | Download SDF |
PubChem ID | 65571 | Appearance | White powder |
Formula | C22H28O6 | M.Wt | 388.5 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Synonyms | Nigakilactone D | ||
Solubility | Soluble in methan | ||
SMILES | CC1C=C(C(=O)C2(C1CC3C4(C2C(=O)C(=C(C4CC(=O)O3)C)OC)C)C)OC | ||
Standard InChIKey | IOSXSVZRTUWBHC-LBTVDEKVSA-N | ||
Standard InChI | InChI=1S/C22H28O6/c1-10-7-14(26-5)20(25)22(4)12(10)8-15-21(3)13(9-16(23)28-15)11(2)18(27-6)17(24)19(21)22/h7,10,12-13,15,19H,8-9H2,1-6H3/t10-,12+,13+,15-,19+,21-,22+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Quassin exhibits P. falciparum inhibitory activity (IC50=0.06 micro g/ml, 0.15 micro M). 2. Quassin can significantly increase red blood cell count, pack cell volume and haemoglobin concentration, suggests that it possesses anti-anaemic property. 3. Quassin has female anti-fertility properties, possibly acting via inhibition of estrogen secretion. 4. Quassin alters the immunological patterns of murine macrophages through generation of nitric oxide to exert antileishmanial activity. |
Targets | Estrogen receptor | Antifection | NO | NOS | IL Receptor | TNF-α | Progestogen receptor |
Quassin Dilution Calculator
Quassin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.574 mL | 12.87 mL | 25.74 mL | 51.4801 mL | 64.3501 mL |
5 mM | 0.5148 mL | 2.574 mL | 5.148 mL | 10.296 mL | 12.87 mL |
10 mM | 0.2574 mL | 1.287 mL | 2.574 mL | 5.148 mL | 6.435 mL |
50 mM | 0.0515 mL | 0.2574 mL | 0.5148 mL | 1.0296 mL | 1.287 mL |
100 mM | 0.0257 mL | 0.1287 mL | 0.2574 mL | 0.5148 mL | 0.6435 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Neoquassine
Catalog No.:BCN3120
CAS No.:76-77-7
- Rhynchophylline
Catalog No.:BCN4979
CAS No.:76-66-4
- Bornyl isobutyrate
Catalog No.:BCC8134
CAS No.:50277-27-5
- Oxymorphone
Catalog No.:BCC5255
CAS No.:76-41-5
- Triamcinolone Acetonide
Catalog No.:BCC3871
CAS No.:76-25-5
- Camphor
Catalog No.:BCN8297
CAS No.:76-22-2
- Pancreatic Polypeptide (human)
Catalog No.:BCC5711
CAS No.:75976-10-2
- 11-Hydroxycanthin-6-one
Catalog No.:BCN3104
CAS No.:75969-83-4
- [Nle4,D-Phe7]-α-MSH
Catalog No.:BCC5963
CAS No.:75921-69-6
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
- 1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone
Catalog No.:BCC1481
CAS No.:758679-97-9
- Rimcazole dihydrochloride
Catalog No.:BCC7090
CAS No.:75859-03-9
- Tephrosin
Catalog No.:BCN4742
CAS No.:76-80-2
- Trityl Chloride
Catalog No.:BCC2805
CAS No.:76-83-5
- Mepenzolate Bromide
Catalog No.:BCC3809
CAS No.:76-90-4
- Conopharyngine
Catalog No.:BCN3975
CAS No.:76-98-2
- H-DL-Nva-OH
Catalog No.:BCC3303
CAS No.:760-78-1
- Lanatin
Catalog No.:BCC8194
CAS No.:76026-24-9
- 3-Epikatonic acid
Catalog No.:BCN4308
CAS No.:76035-62-6
- Broussonin C
Catalog No.:BCN4588
CAS No.:76045-49-3
- 1-Dehydro-6-gingerdione
Catalog No.:BCN3265
CAS No.:76060-35-0
- Myricoside
Catalog No.:BCC8342
CAS No.:76076-04-5
- Artocarpin
Catalog No.:BCN4309
CAS No.:7608-44-8
- SCH 28080
Catalog No.:BCC7154
CAS No.:76081-98-6
Reproductive activities of female albino rats treated with quassin, a bioactive triterpenoid from stem bark extract of Quassia amara.[Pubmed:22314945]
Niger J Physiol Sci. 2010 Nov 24;25(2):95-102.
To evaluate the effect of Quassin on female reproductive functions, 42 albino rats (35 females and 7 males) were used. The female albino rats were divided into seven groups of five rats each. Group I served as the control group and received distilled water while Groups II, III and IV rats were treatedorally with 0.1mg/kg, 1.0 mg/kg and 2.0 mg/kg body weight of Quassin for 60 days respectively. Groups V, VI and VII rats were also treated orally with 0.1 mg/kg, 1.0mg/kg and 2.0 mg/kg body weight of Quassin for 60 days but were left untreated for another 30 days, to serve as the recovery groups. At the end of each experimental period, blood samples were collected from each rat. Fertility study was done by cohabiting one untreated male with the five female rats in each group for 10 days. Quassin did not adversely affect the weight of the kidney, heart, liver and the body of the rats. However there was a significant decrease in the weight of the ovary and uterus in all the groups relative to the control. There was also a significant decrease in serum estrogen levels in Quassin treated rats. The Quassin treated rats had a significantly decreased mean litter number and weight. Histological studies show a disorganization and degeneration in the ovary while the uterus showed signs of vacuolation and disorganization. However, these effects were ameliorated after Quassin was withdrawn from the rats. The results suggest that Quassin has female anti-fertility properties, possibly acting via inhibition of estrogen secretion.
Effects of bioactive principles from stem bark extract of Quassia amara, Quassin and 2-methoxycanthine-6-one, on haematological parameters in albino rats.[Pubmed:22314946]
Niger J Physiol Sci. 2010 Nov 28;25(2):103-6.
The effect of Quassia amara extract and two isolated compounds from the extract, Quassin and 2-methoxycathine-6-one on haematological parameters was studied in rats. All doses of the extract and those of the Quassin significantly increased red blood cell count, packed cell volume and haemoglobin concentration.However, there was no significant increase in the total white blood cell count.There was also no significant change in all parameters studied with 2-methoxycanthine-6-one. The results suggest that quassia extract possesses antianaemic property.
Plasmodium falciparum: in vitro interaction of quassin and neo-quassin with artesunate, a hemisuccinate derivative of artemisinin.[Pubmed:20036657]
Exp Parasitol. 2010 Apr;124(4):421-7.
Quassia amara L. (Family Simaroubaceae) is known to have several medicinal properties including the activity against malaria. An HPLC method was employed for purification of the biologically active Quassinoids; Quassin (Q) and neo-Quassin (NQ), further characterized by MALDI-TOF analyses. Purified Q, NQ and the crude bark extract (S1) along with artesunate (AS) were studied for their in vitro anti-plasmodial activity. The in vivo toxicity studies at intraperitoneal doses with higher concentrations of the crude bark extract (S1) in Balb/C mice ruled out the apprehension of toxicity. Interaction studies between the test compounds among themselves (Q+NQ) and individually with artesunate (AS+Q, AS+NQ), were carried out in vitro at four ratios (1:5, 1:2, 2:1 and 5:1) on chloroquine sensitive (MRC-pf-20) and resistant (MRC-pf-303) strains of Plasmodium falciparum. The crude bark extracts of Q. amara exhibited higher P. falciparum inhibitory activity (IC(50)=0.0025 microg/ml) as compared to that of the isolated compounds, Quassin (IC(50)=0.06 microg/ml, 0.15 microM), neo-Quassin (IC(50)=0.04 microg/ml, 0.1 microM) and also to the positive control, artesunate (IC(50)=0.02 microg/ml, 0.05 microM). The in vitro drug interaction study revealed the compounds, Quassin and neo-Quassin to be additive to each other. At lower ratios, artesunate was found to be a potential combination partner with both the compounds. It was interesting to note that none of the combinations exhibited antagonistic interactions. This phenomenon offers the opportunity for further exploration of novel therapeutic concentrations and combinations.